Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation.
An interventional, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.
DiagnosisASCVD, CKD and systemic inflammation.
ASCVD, CKD and systemic inflammation.
- ziltivekimab 15 mg/mL single-use pre-filled syringe (1 mL)
- placebo single-use pre-filled syringe (1 mL)
For more information, visit clinicaltrials.gov.